Vanguard Capital Management
RLMD icon

Vanguard Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Vanguard Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.9M Buy
4,460,210
+1,383,640
+45% +$9.67M ﹤0.01% 2199
2026
Q1 		$21.4M Buy
+3,076,570
New +$14.6M ﹤0.01% 2301

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's RLMD Position: Q2 2026 in Review

Vanguard Capital Management increased its Relmada Therapeutics (RLMD) stake by 45% in Q2 2026, buying an estimated $9.67M and bringing the position to 4,460,210 shares worth $30.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2199.

Vanguard Capital Management first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Vanguard Capital Management held 4,460,210 shares of Relmada Therapeutics worth $30.9M as of Q2 2026.
  • Vanguard Capital Management bought 1,383,640 Relmada Therapeutics shares in Q2 2026, an estimated $9.67M.
  • Relmada Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2199 holding.
  • Vanguard Capital Management first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.